🇺🇸 FDA

Company profile · Sponsor

Kiniksa

Kiniksa Pharmaceuticals International, plc

KNSA · NYSE pharma LONDON, USA
Pipeline
14
Drugs
0
Patents
8

Quick answer

Kiniksa (KNSA) is a pharma company. headquartered in LONDON, USA. listed on NYSE. NovaPharmaNews links 14 pipeline programs, 0 drugs, and 8 patents to this profile..

Company facts

Ticker KNSA
Exchange NYSE
Company type pharma
Headquarters LONDON, USA
SEC CIK 0001730430

Pipeline (14)

Search pipeline →

  1. KPL-387

    Kiniksa

    Pericarditis

    phase 3 small molecule active

    1 trial

  2. Rilonacept

    Kiniksa

    Recurrent Pericarditis

    phase 3 small molecule completed

    1 trial

  3. mavrilimumab

    Kiniksa

    COVID

    phase 3 small molecule completed

    1 trial

  4. A sterile preservative-free solution with identical composition as the drug product, but without the protein.

    Kiniksa

    Sjögren’s Disease

    phase 2 small molecule active

    1 trial

  5. Abiprubart

    Kiniksa

    Sjögrens Disease

    phase 2 small molecule terminated

    1 trial

  6. KPL-387

    Kiniksa

    Recurrent Pericarditis

    phase 2 small molecule active

    1 trial

  7. KPL-387

    Kiniksa

    Well-Controlled Recurrent Pericarditis

    phase 2 small molecule active

    1 trial

  8. KPL-404

    Kiniksa

    Arthritis, Rheumatoid

    phase 2 small molecule completed

    1 trial

  9. KPL-716

    Kiniksa

    Chronic Idiopathic Urticaria

    phase 2 small molecule completed

    1 trial

  10. KPL-914

    Kiniksa

    Recurrent Pericarditis

    phase 2 small molecule completed

    1 trial

  11. Mavrilimumab

    Kiniksa

    COVID-19

    phase 2 small molecule completed

    3 trials

  12. Vixarelimab

    Kiniksa

    Prurigo Nodularis

    phase 2 small molecule completed

    1 trial

  13. mavrilimumab

    Kiniksa

    Giant Cell Arteritis

    phase 2 other completed

    1 trial

  14. KPL-404

    Kiniksa

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

Patents (8)

Search patents →

  1. US 12234294

    Pharmaceutical composition of a humanized anti-CD40 antibody

    Expires Mon Feb 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12122837

    Oncostatin M receptor antigen binding proteins

    Expires Mon Oct 17 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 11141479

    Stable anti-OSMR antibody formulation

    Expires Mon Oct 07 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 10493149

    Stable anti-OSMR antibody formulation

    Expires Mon Nov 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 10421813

    Oncostatin M receptor antigen binding proteins

    Expires Mon Sep 19 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 10391170

    Stable anti-OSMR antibody formulation

    Expires Mon Aug 22 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 9738721

    Oncostatin M receptor antigen binding proteins

    Expires Mon Aug 17 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 9663571

    Oncostatin M receptor antigen binding proteins

    Expires Mon May 25 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is Kiniksa?

Kiniksa (KNSA) is a pharma company. headquartered in LONDON, USA. listed on NYSE. NovaPharmaNews links 14 pipeline programs, 0 drugs, and 8 patents to this profile..

What pipeline programs does Kiniksa sponsor?

We track 14 ClinicalTrials.gov-linked programs for Kiniksa, including KPL-387 and 13 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Kiniksa company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.